|
VistaTrak Calendar |
The calendar of events page provides details of upcoming events featuring VistaTrak.
Society of Computed Body Tomography & Magnetic Resonance 2009 Annual Course
March 1 - 5, 2009
Miami, FL
www.scbtmr.org 
American Healthcare Radiology Administrators 2009 Spring Conference
April 14 - 16, 2009
New Orleans, LA
www.ahraonline.org
Radiology Business Management Association 2009 Summit
June 7 - 10, 2009
Orlando, FL
www.rbma.org
2009 Annual Meeting of the FRS & FRBMA
July 17-19, 2009
Palm Beach, FL
www.flrad.org
Association for Healthcare Resource & Materials Management Annual Conference and Exposition
July 19 - 21, 2009
Tampa, FL
www.ahrmm.org
American Healthcare Radiology Administrators 2009 Annual Meeting and Exposition
August 9 - 13, 2009
Las Vegas, NV
www.ahraonline.org
American Healthcare Radiology Administrators 2009 Fall Conference
September 29 - October 1, 2009
Nashville, TN
www.ahraonline.org
Radiology Society of North America 95th Scientific Assembly and Annual Meeting
November 29 - December 3, 2009
Chicago, IL
www.rsna.org
American Society of Health-System Pharmacists Mid Year Clinical Meeting
December 6 - 10, 2009
Las Vegas, NV
www.ashp.org
INDICATIONS and IMPORTANT SAFETY INFORMATION
MAGNEVIST® (gadopentetate dimeglumine) Injection
INDICATIONS AND USAGE
Central Nervous System: MAGNEVIST® (gadopentetate dimeglumine) Injection is indicated for use with magnetic resonance imaging (MRI) in adults, and pediatric patients (2 years of age and older) to visualize lesions with abnormal vascularity in the brain (intracranial lesions), spine and associated tissues. MAGNEVIST Injection has been shown to facilitate visualization of intracranial lesions including but not limited to tumors.
Extracranial/Extraspinal Tissues: MAGNEVIST is indicated for use with MRI in adults and pediatric patients (2 years of age and older) to facilitate the visualization of lesions with abnormal vascularity in the head and neck.
Body: MAGNEVIST Injection is indicated for use in MRI in adults and pediatric patients (2 years of age and older) to facilitate the visualization of lesions with abnormal vascularity in the body (excluding the heart).
IMPORTANT SAFETY INFORMATION
WARNING: NEPHROGENIC SYSTEMIC FIBROSIS
Gadolinium-based contrast agents increase the risk for nephrogenic systemic fibrosis (NSF) in patients with:
- acute or chronic severe renal insufficiency (glomerular filtration rate < 30 mL/min/1.73m2), or
- acute renal insufficiency of any severity due to the hepato-renal syndrome or in the perioperative liver transplantation period.
In these patients, avoid use of gadolinium-based contrast agents unless the diagnostic information is essential and not available with non-contrast enhanced magnetic resonance imaging (MRI). NSF may result in fatal or debilitating systemic fibrosis affecting the skin, muscle and internal organs. Screen all patients for renal dysfunction by obtaining a history and/or laboratory tests. When administering a gadolinium-based contrast agent, do not exceed the recommended dose and allow a sufficient period of time for elimination of the agent from the body prior to any readministration.
The possibility of serious or life-threatening anaphylactic or anaphylactoid reactions, including cardiovascular, respiratory, and/or cutaneous manifestations, should always be considered. As with other paramagnetic contrast agents, caution should be exercised in patients with renal insufficiency due to the possibility of further deterioration in renal function. As with other injectable products, cases of phlebitis and thrombophlebitis have been reported; assessment of the dosed limb for the development of injection site reactions is recommended.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.
For important risk and use information, please see the full prescribing information.
EOVIST® (gadoxetate disodium) Injection
INDICATIONS AND USAGE
EOVIST® (gadoxetate disodium) Injection is a gadolinium-based contrast agent indicated for intravenous use in T1-weighted magnetic resonance imaging (MRI) of the liver to detect and characterize lesions in adults with known or suspected focal liver disease.
IMPORTANT SAFETY INFORMATION
WARNING: NEPHROGENIC SYSTEMIC FIBROSIS
Gadolinium-based contrast agents increase the risk for nephrogenic systemic fibrosis (NSF) in patients with:
- acute or chronic severe renal insufficiency (glomerular filtration rate < 30 mL/min/1.73m2), or
- acute renal insufficiency of any severity due to the hepato-renal syndrome or in the perioperative liver transplantation period.
In these patients, avoid use of gadolinium-based contrast agents unless the diagnostic information is essential and not available with non-contrast enhanced magnetic resonance imaging (MRI). NSF may result in fatal or debilitating systemic fibrosis affecting the skin, muscle and internal organs. Screen all patients for renal dysfunction by obtaining a history and/or laboratory tests. When administering a gadolinium-based contrast agent, do not exceed the recommended dose and allow a sufficient period of time for elimination of the agent from the body prior to any readministration.
The possibility of serious or life-threatening anaphylactoid/hypersensitivity reactions with cardiovascular, respiratory and/or cutaneous manifestations should always be considered. The most common adverse reactions observed in clinical trials at the recommended dose included feeling hot, nausea and headache.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.
For important risk and use information, please see the full prescribing information.
ULTRAVIST® (iopromide) Injection
INDICATIONS AND USAGE
ULTRAVIST® (iopromide) Injection is an iodinated contrast agent indicated for:
Intra-arterial Procedures*: 150 mgI/mL for intra-arterial digital subtraction angiography (IA-DSA); 300 mgI/mL for cerebral arteriography and peripheral arteriography; 370 mgI/mL for coronary arteriography and left ventriculography, visceral angiography, and aortography.
Intravenous Procedures*: 240 mgI/mL for peripheral venography; 300 mgI/mL for excretory urography; 300 mgI/mL and 370 mgI/mL for contrast Computed Tomography (CT) of the head and body (intrathoracic, intra-abdominal and retroperitoneal regions) for the evaluation of neoplastic and non-neoplastic lesions. The usefulness of contrast enhancement for the investigation of the retrobulbar space and of low grade or infiltrative glioma has not been demonstrated.
*For information on the concentrations and doses for the Pediatric Population [see Dosage and Administration (2.3) and Use in Specific Populations (8.4) in the full prescribing information].
IMPORTANT SAFETY INFORMATION
WARNING: NOT FOR INTRATHECAL USE
Inadvertent intrathecal administration may cause death, convulsions, cerebral hemorrhage, coma, paralysis, arachnoiditis, acute renal failure, cardiac arrest, seizures, rhabdomyolysis, hyperthermia, and brain edema.
CONTRAINDICATIONS
ULTRAVIST Injection is contraindicated for intrathecal use.
Preparatory dehydration (e.g. prolonged fasting and the administration of a laxative before ULTRAVIST Injection) is contraindicated in pediatric patients because of risk of renal failure.
WARNINGS AND PRECAUTIONS
Life-threatening or fatal anaphylactoid reactions may occur during or after Ultravist administration. Acute renal failure may occur following ULTRAVIST administration, particularly in patients with renal insufficiency, diabetes, multiple myeloma. Hemodynamic disturbances including shock and cardiac arrest may occur during or shortly after administration of ULTRAVIST. Angiography may be associated with local and distal organ damage, ischemia, thromboembolism and organ failure.
MOST COMMON ADVERSE REACTIONS
Most common adverse reactions (>1%) are headache, dysguesia, abnormal vision, chest pain, vasodilatation, nausea, vomiting, back pain, urinary urgency, injection site and infusion site reactions, and pain.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.
For important risk and use information, please see the full prescribing information.
|
|
|
|
|
